On Tuesday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) opened lower -2.44% from the last session, before settling in for the closing price of $6.96. Price fluctuations for PHAT have ranged from $6.07 to $19.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -37.62% at the time writing. With a float of $34.87 million, this company’s outstanding shares have now reached $68.32 million.
Considering the fact that the conglomerate employs 452 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 85.02%, operating margin of -1096.02%, and the pretax margin is -1292.14%.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Phathom Pharmaceuticals Inc is 49.01%, while institutional ownership is 68.80%. The most recent insider transaction that took place on Dec 19 ’24, was worth 8,944. In this transaction Chief Operating Officer of this company sold 1,118 shares at a rate of $8.00, taking the stock ownership to the 239,303 shares. Before that another transaction happened on Dec 19 ’24, when Company’s CFO and CBO sold 1,291 for $8.00, making the entire transaction worth $10,328. This insider now owns 98,156 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -37.62% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Check out the current performance indicators for Phathom Pharmaceuticals Inc (PHAT). In the past quarter, the stock posted a quick ratio of 5.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.69, a number that is poised to hit -1.21 in the next quarter and is forecasted to reach -4.12 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Compared to the last year’s volume of 0.97 million, its volume of 1.07 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 36.19%. Additionally, its Average True Range was 0.58.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 3.29%, which indicates a significant decrease from 22.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.41% in the past 14 days, which was lower than the 90.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.88, while its 200-day Moving Average is $11.95. Nevertheless, the first resistance level for the watch stands at $7.06 in the near term. At $7.33, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.69. If the price goes on to break the first support level at $6.43, it is likely to go to the next support level at $6.08. Should the price break the second support level, the third support level stands at $5.81.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
There are currently 68,377K shares outstanding in the company with a market cap of 464.28 million. Presently, the company’s annual sales total 680 K according to its annual income of -201,590 K. Last quarter, the company’s sales amounted to 16,350 K and its income totaled -85,580 K.
